Use of the anti-parasitic drug ivermectin could reduce COVID-19 related deaths, data from a peer-reviewed study shows.

This program limits the prices drug manufacturers can charge for therapies sold to specific healthcare facilities, including public hospitals and community health centers.

GSK CEO Emma Walmsley may face some contentious opposition from key investors interested in forcing a management change following the planned investor update.

Though the world is reopening, this pandemic is not over. Moderna continues expanding production to answer the call globally.

The new U.S. HQ for Neogene has the backing of biotech guru Arie Belldegrun, CEO of Kite Pharma. The company has leased 38,000 sq. ft. in two Santa Monica buildings.

Incyte had a particularly big week scheduled with the U.S. FDA, which included two PDUFA dates and an advisory committee meeting. In addition, Ascendis had a target action date.

Researchers at the virtual 7th Congress of the European Academy of Neurology consistently report significant, lingering cognitive and behavioral problems in multiple studies.

It was another busy week of clinical trial announcements. Here’s a look.

The U.S. CDC issued new guidance for long COVID, and the NIH is figuring out how to deal with the disease, while Tonix Pharma plans to develop TNX-102 SL.

AstraZeneca today welcomed the ruling by the Court of First Instance in Brussels. The European Commission had requested 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021. The judge ordered delivery of 80.2 million doses by 27 September 2021.

Eisai believes this is a potential-best in class FRα ADC that has shown single agent activity in patients with advanced solid tumors, including endometrial, ovarian, lung and breast cancers.

The FDA said that the drug, which has been studied and submitted for NPC indication, needs further data to support its use in this rare, progressive genetic disorder.

In its announcement, the company did not specify why Kawas’ doctoral research was under investigation, only saying it did not intend to comment on the issue until it had been resolved.

New data shows Zolgensma, Novartis’ gene therapy for spinal muscular atrophy, has the potential to be used presymptomatically in juveniles.

Three other drug contenders that work similarly to Biogen’s drug are currently in clinical trials and expecting data relatively soon.

The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

In the report to the Committee on the Judiciary in the U.S. Senate, the GAO says drug makers have spent nearly $8.2 billion on DTC drug ads in three therapeutic areas from 2016 to 2018.

Findings from the study suggest the oral JAK inhibitor tofacitinib could be a potential contender in the race to identify benefits for COVID-19 in already approved therapies.